Sugi Predict
/ Targets
/ HCK
Top predicted compounds (top 20 by supporting neighbours, then confidence)
Clinical trials — most relevant to HCK by text similarity (a relevance ranking, not an exhaustive list)
| Trial | Phase | Status |
|---|
| Phase II Dasatinib Study in Advanced Breast Cancer |
PHASE2 | COMPLETED |
| A Phase II Study of Dasatinib in the Treatment of Relapsed or Plateau Phase Multiple Myeloma |
PHASE2 | COMPLETED |
| CIK-Cells in Relapsing Patients With Acute Leukemia or Myelodysplastic Syndromes After SCT. |
PHASE1/PHASE2 | UNKNOWN |
| Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Therapy |
PHASE2 | COMPLETED |
| Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer |
PHASE2 | RECRUITING |
| AZD0530 to Treat Recurrent Stage IIIB/IV NSCLC Previously Treated With Combination Chemotherapy |
PHASE2 | COMPLETED |
| Tipifarnib in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia |
PHASE2 | COMPLETED |
| Immunomodulating Therapy and Improved Vaccination Responses by Cox-2 Inhibitor in HIV-infected Patients |
PHASE2 | COMPLETED |
| Dual-Target HER2/CEA CAR-NK Cells in Advanced Biliary Tract Cancer |
PHASE1/PHASE2 | RECRUITING |
| A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies |
PHASE1/PHASE2 | RECRUITING |
| LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations |
PHASE2 | COMPLETED |
| Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma |
PHASE2 | ACTIVE_NOT_RECRUITING |
| A Study of Anti-PD-1 Combinations of D-CIK Immunotherapy and Axitinib in Advanced Ranal Carcinoma |
PHASE2 | UNKNOWN |
| ASLAN001 in Patients With Advanced or Metastatic Cholangiocarcinoma Who Progressed on at Least 1 Line of Systemic Therapy |
PHASE2 | COMPLETED |
| A Study of JNJ-64264681 and JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia |
PHASE1 | COMPLETED |
| CD45BE-HSPC + CART-45 Cells |
PHASE1 | RECRUITING |
| A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) |
PHASE1 | ACTIVE_NOT_RECRUITING |
| Safety,PK/PD, Food Effect Study of Orally Administered HM71224 in Healthy Adult Male Volunteers |
PHASE1 | COMPLETED |
| Imatinib to Increase RUNX1 Activity in Participants With Germline RUNX1 Deficiency |
PHASE1 | RECRUITING |
| HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL |
PHASE1 | WITHDRAWN |
| A Study to Evaluate the Effect of Ibrutinib on the Pharmacokinetics of Oral Contraceptives, CYP2B6, and CYP3A4 Substrates in Female Participants With B Cell Malignancy |
PHASE1 | COMPLETED |
| A Study of the MALT1 Inhibitor JNJ-67856633 and Ibrutinib in Combination in B-cell NHL and CLL |
PHASE1 | COMPLETED |
| The Treatment of Advanced Lung Cancer With Dribbles Antigen by Targeting Activation of Tcells |
PHASE1 | UNKNOWN |
| Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2 |
PHASE1 | COMPLETED |
| Bristol-Myers Squibb Dasatinib Src Inhibition in Endometrial Cancer |
EARLY_PHASE1 | COMPLETED |
| Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212 |
EARLY_PHASE1 | COMPLETED |
| Pathogenesis of BTK-mediated Hyper-Inflammatory Responses in COVID-19 (RESPOND) |
nan | WITHDRAWN |
| A Retrospective Study to Determine the Incidence of NTRK Fusions. NTRK Study |
nan | COMPLETED |
| NTRK 1,2,3 Rearrangements in Patients With Solid Tumors |
nan | ACTIVE_NOT_RECRUITING |
| Ibrutinib Adapted to Response in Patients With CLL |
nan | UNKNOWN |
Related proteins — ESM-2 sequence neighbours (a HCK binder may also engage these)